Wang et al. [124] used a comprehensive screen to pinpoint RBM39 as a crucial RBP necessary for AML survival, and demonstrated therapeutic effects by pharmacologically reducing RBM39 protein in spliceosome mutant AML models. This evidence concerns the gene RBM39 and acute myeloid leukemia.